WENSENG “WENDY” PAN focuses on mergers and acquisitions, technology-based transactions and strategic partnerships, especially in the life sciences industry and in cross-border settings. One of her client’s said that she “is an incredibly intelligent lawyer who finds solutions for her clients. She is very personable and responsive – very good to deal with. I recommend her highly.”
She has advised private equity firms in leveraged buyouts and has represented financial institutions, technology, media and telecoms (TMT), biopharmaceutical, manufacturing, publishing, electronics companies and retail chains in stock and/or cash acquisitions, mergers, tender offers and going-private transactions. Wendy has advised on mergers and acquisitions transactions with an aggregate value over US$10 billion. She also represents VC firms and start-up and growth stage companies in venture capital and pre-IPO financings. Wendy represented BGI-Shenzhen in its acquisition of a U.S. Nasdaq company, which is the first successful acquisition of a U.S. public company by a Chinese company.
Wendy has advised life sciences companies and technology companies in structuring and negotiating complex IP-based transactions and other commercial arrangements. Her practice covers product and technology licensing, strategic partnerships and joint venture formations and research, product development and commercialization collaborations, as well as mergers and acquisitions and private investments. As a former scientist and a registered U.S. patent lawyer, Wendy possesses a diverse set of skills for counseling her clients on intellectual property related issues in non-contentious settings.
Wendy’s experience in representing U.S. companies in their sale to Chinese buyers, as well as Chinese companies in cross-border investments and acquisitions.